Optimization of Treatment With Infliximab in a Medical Setting.

Trial Profile

Optimization of Treatment With Infliximab in a Medical Setting.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms OPTIMIST
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 21 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Additional primary endpoints added as reported by ClinicalTrials.gov.
    • 28 Sep 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top